Category - Developments

Developments

Cellect CEO to be keynote speaker at regenerative medicine conference

Cellect Biotechnology (NASDAQ, TASE:APOP) CEO, Dr. Shai Yarkoni, was selected to provide the keynote presentation at the 11th World Congress of Regenerative Medicine and Stem Cell Technologies in Singapore. The event is...

November 10, 2017

Developments

IntelGenx seeks Health Canada approval for montelukast VersaFilm trial

IntelGenx (OTCQX:IGXT; TSXV:IGX) submitted a clinical trial application to Health Canada for approval to initiate a Phase 2a proof-of-concept study with montelukast in mild-to-moderate Alzheimer’s disease (AD)...

November 10, 2017

Developments

Profound Medical expands use of TULSA-PRO to BPH

Profound Medical (OTCQX:PRFMF; TSXV:PRN) announced that benign prostatic hyperplasia (BPH) treatments utilizing TULSA-PRO are now being successfully conducted in Germany. BPH is a non-cancerous enlargement of the...

November 6, 2017

Developments

Flex Pharma reports positive Phase 2 ALS cramping data

Flex Pharma (NASDAQ:FLKS) announced positive topline data for FLX-787 from its placebo-controlled, crossover Australian trial in amyotrophic lateral sclerosis (ALS) patients with frequent muscle cramps. The study was...

November 6, 2017

Developments

IntelGenx, RedHill Biopharma resubmit RIZAPORT NDA to FDA

IntelGenx (OTCQX:IGXT; TSXV:IGX) and RedHill Biopharma (NASDAQ, TASE:RDHL) resubmitted the 505(b)(2) NDA to the FDA for RIZAPORT 10 mg, an oral thin-film formulation of rizatriptan for the treatment of acute migraines...

November 1, 2017

Developments

Oramed gets EU notice of broad patent claims for oral proteins

The European Patent Office has issued to Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) a notice of intent to grant a patent for broader claims for its invention titled, “Methods and Compositions for Oral Administration of...

October 31, 2017

Developments

Mateon updates Phase 1b AML data

Mateon Therapeutics (OTCQX:MATN) announced updated data from the fifth dose cohort of OX1222, a Phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid...

October 30, 2017

Developments

Asthma medicine montelukast might protect against dementia

An article published in the journal, Immunity & Aging, suggests that the leukotriene receptor antagonist, Montelukast, rejuvenates aged brains in rats. The authors of the article question whether the commonly used...

October 23, 2017

Developments

Titan Pharma presents non-clinical hypothyroidism implant data

Titan Pharmaceuticals (NASDAQ:TTNP) presented non-clinical data on the use of its ProNeura subdermal implant for the long-term, sustained delivery of liothyronine (L-T3) at the annual conference of the American Thyroid...

October 20, 2017

Developments

Echelon adds top pick status to Immunovaccine

Echelon Wealth Partners ascribed 2017 top pick status to Immunovaccine (TSX:IMV; OTCQX:IMMVF) while maintaining a “speculative buy” rating and $2.75 price target. The stock closed at $1.24 on Oct. 11. Analyst Doug Loe...

October 12, 2017

Category - Developments

Cellect CEO to be keynote speaker at regenerative medicine conference

IntelGenx seeks Health Canada approval for montelukast VersaFilm trial

Profound Medical expands use of TULSA-PRO to BPH

Flex Pharma reports positive Phase 2 ALS cramping data

IntelGenx, RedHill Biopharma resubmit RIZAPORT NDA to FDA

Oramed gets EU notice of broad patent claims for oral proteins

Mateon updates Phase 1b AML data

Asthma medicine montelukast might protect against dementia

Titan Pharma presents non-clinical hypothyroidism implant data

Echelon adds top pick status to Immunovaccine

General

More